KUR-502 is under clinical development by Athenex and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KUR-502’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KUR-502 is under development for the treatment of relapsed/refractory acute lymphocytic leukemia including b-cell acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia R/R chronic lymphocytic leukemia and diffuse large B-cell lymphoma. The drug candidate comprises of genetically engineered natural killer T cells (NKT cells) that expresses chimeric antigen receptor (CAR) on its surface in a retroviral vector. It is developed based on allogeneic chimeric antigen receptor-natural killer T cell (CAR-NKT) technology. It acts by targeting cells expressing CD19.
Athenex, formerly known as Kinex Pharmaceuticals, is a biopharmaceutical company focused on the discovery, development of autologous and allogeneic CAR-NKT cell therapies to treat cancers. The company’s product pipeline includes KUR-501–GD2, KUR-502–CD19, KUR-503–GPC3 and p53-KRAS and EGFR. Athenex platform includes oncology innovation Platform for research and development, commercial platform for manufacturing and marketing of products and global supply chain which provide APIS to clinical and commercial effort. The company partners with pharmaceutical companies, universities and research institutions for the advancement and commercialization of its products. It has operations with product manufacturing facilities in the US, China, Taiwan and Hong Kong. Athenex is headquartered in Buffalo, New York, the US.
For a complete picture of KUR-502’s drug-specific PTSR and LoA scores, buy the report here.